logo-loader
viewFutura Medical PLC

Futura Medical CEO talks regulatory timeline and commercial potential for breakthrough gel

Futura Medical PLC's (LON:FUM)  James Barder caught up with Proactive London's Andrew Scott on the back of their 2019 results.

He says the EU filing for MED3000 is likely by the end of July, with the US Food & Drug Administration submission expected by the end of the third quarter.

MED3000 is Futura's fast-acting gel for erectile dysfunction.

Quick facts: Futura Medical PLC

Price: 15.25 GBX

AIM:FUM
Market: AIM
Market Cap: £37.46 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Futura Medical PLC named herein, including the promotion by the Company of Futura Medical PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Futura Medical gets set to begin formal approval steps for erectile...

Futura Medical PLC’s (LON:FUR) James Barder talks to Proactive London’s Katie Pilbeam about the highlights in their half-year report which includes the latest on MED3000 - a topical treatment for Erectile Dysfunction. Proceedings have begun for formal approval of the drug to be approved as a...

5 days, 21 hours ago

2 min read